Objectives: Chordoma is a rare bone malignancy that affects the spine and skull base. Treatment dilemma leads to a high rate of local relapse and distant metastases. Molecular targeted therapy (MTT) ...

The model constitutes an advance for the study of this malignant disease, laying the groundwork for a broader study to improve the understanding of the neurological deficits that occur when chordoma ...

OBJECT: Metastastic lesions have been reported in 5 to 40% of patients with spinal and sacrococcygeal chordoma, but few contemporary series of chordoma metastastic disease exist in the literature.

10 from the Chordoma Foundation Biobank and 10 from Johns Hopkins University. Clinical variables collected were patient demographics (age, sex, race, and ethnicity), anatomic site of tumor origin ...

ESMO also hosted a parallel consensus meeting on chordoma that included more than 40 chordoma experts from several disciplines and from both sides of the Atlantic, with the contribution and ...

Chordoma research is led by a comprehensive team including Gary Gallia, M.D., director of the Neurosurgery Skull Base Tumor Center. The laboratory focuses on developing new therapies for brain and ...

We, here, report the case of a 72-year-old man who presented with a giant sacral chordoma without aggressive clinical and neurological course and confirmed with a CT guided biopsy. The patient ...

Mac Sinise died Jan. 5 after a five-year battle with chordoma, a rare type of cancer found in the spine. In his final years, he was dedicated to working with his father's foundation and making music.

The Chordoma Foundation and some of its philanthropic partners announced that they will launch a competition offering $500,000 in prizes for the discovery of drugs targeting the protein TBXT, a ...

While Moira Sinise's cancer went into remission, Mac underwent two spinal surgeries but the Chordoma had returned by May 2019. "This began a long battle that disabled him more and more as time ...